Opus Genetics, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Opus Genetics, Inc. (IRD) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 16.31 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-06
- Opus Genetics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 16.31M shares, a 49.41% decline year-over-year.
- Opus Genetics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 34.83M shares, a 7.79% decline year-over-year.
- Opus Genetics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 32.25M shares.
- Opus Genetics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 37.77M shares.
- Opus Genetics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2016 was 7.14M shares, a 82.76% increase from fiscal 2015.
- Opus Genetics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2015 was 3.91M shares, a 84.12% decline from fiscal 2014.
- Opus Genetics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2014 was 24.61M shares, a 28.31% decline from fiscal 2013.
- Opus Genetics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2013 was 34.33M shares, a 16.76% increase from fiscal 2012.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 16.31M shares 10-Q · filed 2026-08-06 | 32.22M shares 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | 34.83M shares 10-Q · filed 2026-05-12 | ||||
| 2025-09-30 | 39.06M shares 10-Q · filed 2025-11-12 | ||||
| 2025-06-30 | 32.25M shares 10-Q · filed 2026-08-06 | 32.25M shares 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | 37.77M shares 10-Q · filed 2026-05-12 | ||||
| 2024-09-30 | 13.18M shares 10-Q · filed 2025-11-12 | ||||
| 2018-03-31 | 9.65M shares 10-Q · filed 2018-05-04 | ||||
| 2017-12-31 | 8.96M shares 10-Q · filed 2018-05-04 | ||||
| 2017-09-30 | 7.17M shares 10-Q · filed 2017-11-03 | ||||
| 2017-06-30 | 7.28M shares 10-Q · filed 2017-08-04 | ||||
| 2017-03-31 | 65.84M shares 10-Q · filed 2017-05-03 | ||||
| 2016-12-31 | 7.14M shares 10-K · filed 2018-03-09 | 71.43M shares 10-K · filed 2017-02-24 | |||
| 2016-09-30 | 72.30M shares 10-Q · filed 2016-11-04 | ||||
| 2016-06-30 | 55.38M shares 10-Q · filed 2016-08-05 | ||||
| 2016-03-31 | 54.92M shares 10-Q · filed 2016-05-06 | ||||
| 2015-12-31 | 3.91M shares 10-K · filed 2018-03-09 | 39.08M shares 10-K · filed 2016-03-14 | |||
| 2015-09-30 | 25.98M shares 10-Q · filed 2015-11-02 | ||||
| 2015-06-30 | 26.01M shares 10-Q · filed 2015-08-07 | ||||
| 2015-03-31 | 25.72M shares 10-Q · filed 2015-05-08 | ||||
| 2014-12-31 | 24.61M shares 10-K · filed 2017-02-24 | ||||
| 2014-09-30 | 25.26M shares 10-Q · filed 2014-11-12 | ||||
| 2014-06-30 | 24.29M shares 10-Q · filed 2014-08-13 | ||||
| 2014-03-31 | 29.17M shares 10-Q · filed 2014-05-14 | ||||
| 2013-12-31 | 34.33M shares 10-K · filed 2016-03-14 | ||||
| 2013-09-30 | 32.36M shares 10-Q · filed 2013-11-13 | ||||
| 2013-06-30 | 31.64M shares 10-Q · filed 2013-08-12 | ||||
| 2013-03-31 | 31.15M shares 10-Q · filed 2013-05-09 | ||||
| 2012-12-31 | 29.40M shares 10-K · filed 2014-03-21 | ||||
| 2012-09-30 | 16.42M shares 10-Q · filed 2012-11-08 | ||||
| 2012-06-30 | 16.52M shares 10-Q · filed 2012-08-08 | ||||
| 2011-12-31 | 16.32M shares 10-Q · filed 2012-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |